Table 2.
In-Hospital Application of Statin and ACEi/ARB in Statin and Non-statin Groups
| Parameters | Unmatched |
Matched |
|||||
|---|---|---|---|---|---|---|---|
| Statin (n = 1,219) | Non-statin (n = 12,762) | p Valueb | Statin (n = 861) | Non-statin (n = 3,444) | SD | p Valueb | |
| Atorvastatin, n (%) | 1,014 (83.2%) | 0 (0.0%) | <0.001 | 730 (84.8%) | 0 (0.0%) | 3.338 | <0.001 |
| Rosuvastatin, n (%) | 190 (15.6%) | 0 (0.0%) | <0.001 | 113 (13.1%) | 0 (0.0%) | 0.550 | <0.001 |
| Simvastatin, n (%) | 22 (1.8%) | 0 (0.0%) | <0.001 | 16 (1.9%) | 0 (0.0%) | 0.195 | <0.001 |
| Pravastatin, n (%) | 16 (1.3%) | 0 (0.0%) | <0.001 | 11 (1.3%) | 0 (0.0%) | 0.161 | <0.001 |
| Fluvastatin, n (%) | 1 (0.1%) | 0 (0.0%) | 0.087 | 0 (0.0%) | 0 (0.0%) | 0.000 | 1.000 |
| Pitavastatin, n (%) | 10 (0.8%) | 0 (0.0%) | <0.001 | 7 (0.8%) | 0 (0.0%) | 0.128 | <0.001 |
| ACEi/ARB, n (%) | 319 (26.2%) | 848 (6.6%) | <0.001 | 154 (17.9%) | 653 (19.0%) | −0.028 | 0.501 |
| Statin initial day after admission, median (IQR), days | 0.0 (0.0–0.0) | – | – | 0.0 (0.0–0.0) | – | – | – |
| Statin therapeutic duration, median (IQR), days | 22.0 (14.0–28.0) | – | – | 21.0 (14.0–28.0) | – | – | – |
| Daily equivalent dose of statina, median (IQR), mg | 20.0 (18.9–20.0) | – | – | 20.0 (17.1–20.0) | – | – | – |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range; SD, standardized difference.
a
Daily equivalent dose of statin was converted to an equivalent dose of atorvastatin according to Hu et al. (2015)
b
p values were calculated by Mann-Whitney U test for non-normally distributed continuous variables and Fisher’s exact test or χ2 test for categorical variables